Adult Malignant Glioma Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: A243C0255051EN
Market Monitor Global

Abstracts

Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.

This report contains market size and forecasts of Adult Malignant Glioma Therapeutics in Global, including the following market information:

Global Adult Malignant Glioma Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Adult Malignant Glioma Therapeutics market was valued at 1329.5 million in 2021 and is projected to reach US$ 1867.9 million by 2028, at a CAGR of 5.0% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Glioblastoma Multiforme Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Adult Malignant Glioma Therapeutics include Merck, Hoffmann-La Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceutical and Teva Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adult Malignant Glioma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Adult Malignant Glioma Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Glioblastoma Multiforme
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Other

Global Adult Malignant Glioma Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers
• Others

Global Adult Malignant Glioma Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Adult Malignant Glioma Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Adult Malignant Glioma Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Merck
• Hoffmann-La Roche
• Arbor Pharmaceuticals
• Pfizer
• AbbVie
• Amgen
• Bristol-Myers Squibb
• Sun Pharmaceutical
• Teva Pharmaceutical
• Novocure
• Eli Lilly
• AstraZeneca
• Novartis AG

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Adult Malignant Glioma Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Adult Malignant Glioma Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Adult Malignant Glioma Therapeutics Market Size: 2021 VS 2028
2.2 Global Adult Malignant Glioma Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Adult Malignant Glioma Therapeutics Players in Global Market
3.2 Top Global Adult Malignant Glioma Therapeutics Companies Ranked by Revenue
3.3 Global Adult Malignant Glioma Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Adult Malignant Glioma Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Adult Malignant Glioma Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Adult Malignant Glioma Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Adult Malignant Glioma Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Glioblastoma Multiforme
  4.1.3 Anaplastic Astrocytoma
  4.1.4 Anaplastic Oligodendroglioma
  4.1.5 Other
4.2 By Type - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Adult Malignant Glioma Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Specialty Clinics
  5.1.4 Cancer and Radiation Therapy Centers
  5.1.5 Others
5.2 By Application - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Adult Malignant Glioma Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Adult Malignant Glioma Therapeutics Revenue, 2017-2028
  6.3.2 US Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.3.3 Canada Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Adult Malignant Glioma Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Adult Malignant Glioma Therapeutics Revenue, 2017-2028
  6.4.2 Germany Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.3 France Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.5 Italy Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.6 Russia Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Adult Malignant Glioma Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Adult Malignant Glioma Therapeutics Revenue, 2017-2028
  6.5.2 China Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.3 Japan Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.6 India Adult Malignant Glioma Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Adult Malignant Glioma Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Adult Malignant Glioma Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.3 Israel Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Adult Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.5 UAE Adult Malignant Glioma Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Merck
  7.1.1 Merck Corporate Summary
  7.1.2 Merck Business Overview
  7.1.3 Merck Adult Malignant Glioma Therapeutics Major Product Offerings
  7.1.4 Merck Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Merck Key News
7.2 Hoffmann-La Roche
  7.2.1 Hoffmann-La Roche Corporate Summary
  7.2.2 Hoffmann-La Roche Business Overview
  7.2.3 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Major Product Offerings
  7.2.4 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Hoffmann-La Roche Key News
7.3 Arbor Pharmaceuticals
  7.3.1 Arbor Pharmaceuticals Corporate Summary
  7.3.2 Arbor Pharmaceuticals Business Overview
  7.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Major Product Offerings
  7.3.4 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Arbor Pharmaceuticals Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Adult Malignant Glioma Therapeutics Major Product Offerings
  7.4.4 Pfizer Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 AbbVie
  7.5.1 AbbVie Corporate Summary
  7.5.2 AbbVie Business Overview
  7.5.3 AbbVie Adult Malignant Glioma Therapeutics Major Product Offerings
  7.5.4 AbbVie Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 AbbVie Key News
7.6 Amgen
  7.6.1 Amgen Corporate Summary
  7.6.2 Amgen Business Overview
  7.6.3 Amgen Adult Malignant Glioma Therapeutics Major Product Offerings
  7.6.4 Amgen Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Amgen Key News
7.7 Bristol-Myers Squibb
  7.7.1 Bristol-Myers Squibb Corporate Summary
  7.7.2 Bristol-Myers Squibb Business Overview
  7.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Major Product Offerings
  7.7.4 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Bristol-Myers Squibb Key News
7.8 Sun Pharmaceutical
  7.8.1 Sun Pharmaceutical Corporate Summary
  7.8.2 Sun Pharmaceutical Business Overview
  7.8.3 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Major Product Offerings
  7.8.4 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Sun Pharmaceutical Key News
7.9 Teva Pharmaceutical
  7.9.1 Teva Pharmaceutical Corporate Summary
  7.9.2 Teva Pharmaceutical Business Overview
  7.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Major Product Offerings
  7.9.4 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Teva Pharmaceutical Key News
7.10 Novocure
  7.10.1 Novocure Corporate Summary
  7.10.2 Novocure Business Overview
  7.10.3 Novocure Adult Malignant Glioma Therapeutics Major Product Offerings
  7.10.4 Novocure Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Novocure Key News
7.11 Eli Lilly
  7.11.1 Eli Lilly Corporate Summary
  7.11.2 Eli Lilly Business Overview
  7.11.3 Eli Lilly Adult Malignant Glioma Therapeutics Major Product Offerings
  7.11.4 Eli Lilly Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.11.5 Eli Lilly Key News
7.12 AstraZeneca
  7.12.1 AstraZeneca Corporate Summary
  7.12.2 AstraZeneca Business Overview
  7.12.3 AstraZeneca Adult Malignant Glioma Therapeutics Major Product Offerings
  7.12.4 AstraZeneca Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.12.5 AstraZeneca Key News
7.13 Novartis AG
  7.13.1 Novartis AG Corporate Summary
  7.13.2 Novartis AG Business Overview
  7.13.3 Novartis AG Adult Malignant Glioma Therapeutics Major Product Offerings
  7.13.4 Novartis AG Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.13.5 Novartis AG Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Adult Malignant Glioma Therapeutics Market Opportunities & Trends in Global Market
Table 2. Adult Malignant Glioma Therapeutics Market Drivers in Global Market
Table 3. Adult Malignant Glioma Therapeutics Market Restraints in Global Market
Table 4. Key Players of Adult Malignant Glioma Therapeutics in Global Market
Table 5. Top Adult Malignant Glioma Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Adult Malignant Glioma Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Adult Malignant Glioma Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Adult Malignant Glioma Therapeutics Product Type
Table 9. List of Global Tier 1 Adult Malignant Glioma Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Adult Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Adult Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Adult Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Adult Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Adult Malignant Glioma Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Adult Malignant Glioma Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Merck Corporate Summary
Table 31. Merck Adult Malignant Glioma Therapeutics Product Offerings
Table 32. Merck Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Hoffmann-La Roche Corporate Summary
Table 34. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Product Offerings
Table 35. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Arbor Pharmaceuticals Corporate Summary
Table 37. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Product Offerings
Table 38. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Adult Malignant Glioma Therapeutics Product Offerings
Table 41. Pfizer Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. AbbVie Corporate Summary
Table 43. AbbVie Adult Malignant Glioma Therapeutics Product Offerings
Table 44. AbbVie Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Amgen Corporate Summary
Table 46. Amgen Adult Malignant Glioma Therapeutics Product Offerings
Table 47. Amgen Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Bristol-Myers Squibb Corporate Summary
Table 49. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Product Offerings
Table 50. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sun Pharmaceutical Corporate Summary
Table 52. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Product Offerings
Table 53. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Teva Pharmaceutical Corporate Summary
Table 55. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Product Offerings
Table 56. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Novocure Corporate Summary
Table 58. Novocure Adult Malignant Glioma Therapeutics Product Offerings
Table 59. Novocure Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Eli Lilly Corporate Summary
Table 61. Eli Lilly Adult Malignant Glioma Therapeutics Product Offerings
Table 62. Eli Lilly Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. AstraZeneca Corporate Summary
Table 64. AstraZeneca Adult Malignant Glioma Therapeutics Product Offerings
Table 65. AstraZeneca Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Novartis AG Corporate Summary
Table 67. Novartis AG Adult Malignant Glioma Therapeutics Product Offerings
Table 68. Novartis AG Adult Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Adult Malignant Glioma Therapeutics Segment by Type in 2021
Figure 2. Adult Malignant Glioma Therapeutics Segment by Application in 2021
Figure 3. Global Adult Malignant Glioma Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Adult Malignant Glioma Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Adult Malignant Glioma Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Adult Malignant Glioma Therapeutics Revenue in 2021
Figure 8. By Type - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Adult Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Merck Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. AbbVie Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Amgen Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Novocure Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Eli Lilly Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. AstraZeneca Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Novartis AG Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)